window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 29, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

influenza prevention

  • Biologics & Biosimilars,Clinical Development,Clinical Trials,Drug approval,Infectious Diseases,Pharmaceuticals and therapeutics,Regulatory Affairs,RNA Therapeutics

    Cidara Therapeutics receives FDA Breakthrough Therapy designation for CD388 in seasonal influenza prevention

    Cidara Therapeutics has received Breakthrough Therapy designation from the US [...]

    October 10, 2025
  • Biotech,Clinical Trials,Pharmaceuticals and therapeutics,Research & Development

    Cidara Therapeutics expands and accelerates phase 3 trial of CD388 for flu prevention

    Cidara Therapeutics has announced an expanded and accelerated Phase 3 [...]

    September 29, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week
    Categories: CDMOs & Manufacturing, Healthcare leadership, Market Access & Commercialization, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top